SIRT1 and systemic lupus erythematosus: Beyond CD4+ cells, SIRT1 inhibition weakens CD8+ T cell cytotoxicity in SLE patients, thereby being impressionable to COVID-19, according to a review based on a search conducted in Medline, Scopus, and WOS (95).